Castle Biosciences, Inc.: Results from a Randomized Controlled Trial Show That TissueCypher Barrett's Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management

Data presented during the 30th United European Gastroenterology (UEG) Week in Vienna, Austria Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide

Related Keywords

Austria ,Vienna ,Wien ,Castle Biosciences ,Allison Marshall ,Camilla Zuckero ,Laboratory Test ,Instagram ,Centers For Medicare Medicaid Services ,Linkedin ,Castle Biosciences Inc ,Twitter ,Nasdaq ,Medicare Clinical Laboratory Fee Schedule ,Laboratory Developed Test ,Securities Exchange ,Facebook ,United European Gastroenterology ,Tissuecypher Barrett ,Esophagus Test ,Esophagus Assay ,Advanced Diagnostic Laboratory Test ,Medicare Medicaid Services ,Mypath Melanoma ,Securities Act ,Securities Exchange Act ,Quarterly Report ,Castle ,Iosciences ,Results ,Rom ,Randomized ,Ontrolled ,Trial ,Show ,Hat ,Issuecypher ,Garrett ,Esophagus ,Pest ,Ignificantly ,Mprove ,Accuracy ,Risk ,Assessments ,Adherence ,Guideline ,Ecommended ,